Lara Longpre

Lara Longpre is a declared insider of Mirum Pharmaceuticals, Inc. (senior executive), with filings sourced from SEC (Form 4). Between 10 September 2019 and 2 February 2024, the trades on record add up to 13 filings.

Both buying and selling appear: 1 purchase worth €9,292, against 3 sales worth €70k. Netting one side against the other leaves €61k of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 9 share grants. In 2024 alone, the filings show 1 purchase and 2 sales.

On 18 March 2024 came the latest disclosure, an open-market purchase for €9,292 in Mirum Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.